Founded in 2002 by President William J. Clinton, the Clinton Health Access Initiative (CHAI) works to broaden access to life-saving treatment for HIV/AIDS, tuberculosis and malaria patients in the poorest parts of the world. As part of this mission, CHAI’s “Access Programs” approach global public health challenges with market-based strategies, using simultaneous engagement on both the supply and demand sides of the market. On the supply side, CHAI engages with suppliers of essential drugs and diagnostics to improve access to products by lowering prices, accelerating new products to market, and sharing market intelligence. On the demand side, CHAI organizes and consolidates demand for health commodities by helping governments to scale up treatment programs, mobilize new resources, improve procurement processes, and enhance local human resource capacity. Working with over 30 governments and other partners, CHAI is focused on large-scale impact on many of the largest barriers to effective treatment and care.
The Laboratory Services Team (LST) is a key source of support for Ministries of Health and CHAI's country teams, and works to address barriers to access and foster a healthy competitive marketplace for essential diagnostic testing. LST plays the lead role in coordinating work globally on access to diagnostics, working closely with diagnostics manufacturers, governments, and multilateral organizations to lower prices, increase access to testing, and accelerate the entry and uptake of new innovative products.
The Country Support Manager (CSM) will work with LST to ensure the rapid scale-up and effective management of high-quality diagnostics for high burden diseases, focusing primarily on diagnostics for patients with HIV and TB. The CSM will work with Ministries of Health and CHAI country teams across multiple focal countries, helping to optimize policies and processes, expand access to high quality diagnostics, ensure that countries have adopted best practices in planning and implementation of testing programs, and support forecasting and procurement of essential diagnostic products. The CSM will also provide support in the quantification and mapping of funding needs against available resources, helping the government to identify funding gaps and design interventions and scale up plans in consideration of current resources.
Historically, the majority of diagnostic testing for HIV and TB has been conducted on conventional, laboratory-based technologies using sample transportation systems to expand access to testing to patients living in rural areas. However, access to these products is limited in many countries, and Ministries of Health require continued support to improve the efficiency of these technologies, expand their reach, and introduce new types of essential tests. In addition, several POC products for diagnosis, disease staging, and treatment monitoring have recently become available or are in development, with the potential to dramatically increase access to treatment, improve patient retention, and make healthcare systems more efficient. These technologies need to be integrated with existing conventional laboratory networks, with an appropriate balance between centralized and decentralized testing.
The CSM will support countries in the implementation of both conventional, laboratory-based diagnostic products and new, innovative point-of-care (POC) products that bring diagnostics out of the laboratory and closer to the patient. In particular, The CSM will support countries in adopting the recently published WHO 2013 guidelines, including the use of viral load (VL) for monitoring patients on anti-retroviral therapy (ART), and developing strategies for scaling up testing programs, which include HIV diagnosis, CD4 testing, Early Infant Diagnosis (EID) and other opportunistic infections. In addition, the CSM will assist countries with the evaluation, adoption and uptake of new POC diagnostic products, which can reduce the burden of undergoing testing, and improve access to essential tests, particularly in rural areas.
The CSM will also support LST in global negotiations with diagnostics manufacturers to lower prices, and with the development of new procurement strategies such as instrument rental deals to enable easier product switching. Finally, the CSM will help develop LST’s market-shaping strategy for fostering competition in the global diagnostics market. In doing so, the CSM will develop strong relationships with various teams within CHAI, as well as Ministries of Health, diagnostics manufacturers, and other external partners in beneficiary countries.
We are seeking a highly motivated individual with outstanding credentials, qualitative and quantitative analytical abilities, and communication skills. The CSM must be able to function independently and flexibly and have a strong commitment to excellence. CHAI places great value on relevant personal qualities: resourcefulness, responsibility, tenacity, independence, energy, work ethic and emotional intelligence.
This is a challenging but rewarding role, which will have direct and near-term impact on thousands of patients in need of life-saving health services. The role will be based in Nigeria with up to 50% travel in the region.
Interestd and suitably qualified candidates should click here to apply online.